Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2018 09:28 ET | Source: InspireMD, Inc.

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE)...
September 24, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico

TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
September 17, 2018 08:00 ET | Source: InspireMD, Inc.

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA...
September 04, 2018 07:30 ET | Source: InspireMD, Inc.

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
August 06, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
July 31, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD Schedules Second Quarter 2018 Earnings Conference Call

Tel Aviv, July 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid...
July 23, 2018 08:41 ET | Source: InspireMD, Inc.

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
June 29, 2018 10:24 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
June 20, 2018 07:20 ET | Source: InspireMD, Inc.

InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil

Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
June 18, 2018 09:42 ET | Source: InspireMD, Inc.

InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery

Study results presented from 46 patients treated over two years with zero complicationsPresident of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of...